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BA = bronchial asthma; BDNF = brain-derived neurotrophic factor; IFN = interferon; IL = interleukin; NGF = nerve growth factor.
Available online http://respiratory-research.com/content/2/5/265
Introduction
BA is a complex disease with several clinically well-
defined pathogenic components, including recurrent
reversible airway obstruction, chronic airway inflammation
and development of airway hyperresponsiveness [1]. The
constituents of the inflammatory component have, in
recent years, been relatively well characterized and
defined. There is now overwhelming evidence that T cells
play a central role in, particularly, allergic BA. Strong evi-
dence supports the notion that T-helper 2 cells orches-
trate allergic inflammation and control many important
aspects of the effector phase response, including recruit-
ment, activation and survival of eosinophils, activation of
mast cells and IgE production. Reversible airway obstruc-
tion is pathogenetically related to mucus hypersecretion,
development of local tissue edema as a consequence of
acute inflammatory responses, and constriction of airway
smooth muscle. Nonspecific bronchial hyperresponsive-
ness may be defined as an increase in the ease and
degree of airway narrowing in response to a wide range of
bronchoconstrictor stimuli. The development of airway
hyperresponsiveness is mediated by multiple independent
and additive pathways working in concert, which can be
clinically tested using stimuli such as methacholine, hista-
mine, exercise, cold air, capsaicin, and so on. Constriction
of airway smooth muscle is largely controlled by sensory
and motor neurons innervating the airways and the lung.
The autonomic nerves that regulate many aspects of
airway function, including airway smooth muscle tone,
mucus secretion and bronchial microcirculation, can be
functionally subdivided into cholinergic, adrenergic and
nonadrenergic noncholinergic pathways.
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Abstract
Allergic bronchial asthma (BA) is characterized by chronic airway inflammation, development of airway
hyperreactivity and recurrent reversible airway obstruction. T-helper 2 cells and their products have
been shown to play an important role in this process. In contrast, the mechanisms by which immune
cells interact with the cells residing in lung and airways, such as neurons, epithelial or smooth muscle
cells, still remains uncertain. Sensory and motor neurons innervating the lung exhibit a great degree of
functional plasticity in BA defined as ‘neuronal plasticity’. These neurons control development of airway
hyperresponsiveness and acute inflammatory responses, resulting in the concept of ‘neurogenic
inflammation’. Such quantitative and/or qualitative changes in neuronal functions are mediated to a
great extent by a family of cytokines, the neurotrophins, which in turn are produced by activated
immune cells, among others in BA. We have therefore developed the concept that neurotrophins such
as nerve growth factor and brain-derived neurotrophic factor link pathogenic events in BA to
dysfunctions of the immune and nervous system.
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Neurogenic inflammation and neuronal
plasticity in BA
Sensory and motor neurons exhibit drastic functional
changes in BA. These changes are defined by the term
‘neuronal plasticity’ [2]. Increased levels of neuropeptides
including substance P have been detected in the lungs of
asthmatic patients [3,4]. Increased levels of Neurokinin A
have been detected in bronchoalveolar lavage fluids of
asthmatic patients following airway allergen challenge.
Since cholinergic nerves represent the dominant bron-
choconstrictor pathway, anticholinergic drugs are very
effective bronchodilators in asthma therapy. This further
underlines the importance of cholinergic mechanisms in
the development of BA and airway hyperresponsiveness.
The underlying mechanisms include enhanced reflex activ-
ity, increased mediator release, enhanced sensitivity of
smooth muscle to neuropeptides and tachykinins, and
increased density of receptor expression of both airway
smooth muscle cells and neurons. In addition to qualitative
changes in neuronal functions, debate still continues
regarding whether quantitative changes in sensory and/or
motor neurons also occur in this disease.
Neuropeptides and tachykinins are involved in several key
features of BA, including airway smooth muscle constric-
tion, vascular dilatation, increased vascular permeability,
mucus hypersecretion and acceleration of airway inflam-
mation. These effects attributed to the function of neu-
ropeptides and tachykinins lead to the concept of
‘neurogenic inflammation’ in BA [5–7].
Neurotrophins
The functional plasticity of sensory and motor neurons is
under close control of neurotrophins. The neurotrophins
nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), neurotrophin-3 and neurotrophin-4/neu-
rotrophin-5 belong to a family of homologous proteins that
exert their effects primarily as target-derived paracrine or
autocrine neurotrophic factors. The role of the neu-
rotrophins in survival, differentiation and maintenance of
neurons is defined well [8]. They exhibit partially overlap-
ping but distinct patterns of expression and cellular
targets. In addition to the effects in the central nervous
system, neurotrophins also effect peripheral afferent and
efferent neurons. The biological effects of neurotrophins
are mediated by binding either to the high affinity
(KD10–11) tyrosine kinese receptors (trkA, trkB, trkC) or
the low affinity (KD10–9) pan-neurotrophin receptor
p75NTR. Substantial biological effects of neurotrophins are
mediated by the high affinity kinese receptors. The high
affinity effector for NGF is trkA, that for BDNF and neu-
rotrophin-4 is trkB, and that for neurotrophin-3 is trkC.
Neurotrophin receptors are widely expressed on the
neurons of the peripheral and the central nervous system,
both during development and in adults. However, trk
receptors as well as p75NTR are also expressed on non-
neuronal cells, including immune cells, muscle cells and
epithelial cells.
The traditional cellular sources of neurotrophins under
physiological conditions are primarily nerve-associated
cells such as glia cells, Schwann cells or fibroblasts and
neurons themselves [8,9]. NGF is also produced in inflam-
matory processes by a wide range of hematopoetic cells,
including mast cells [10], macrophages [11], T cells [12]
and B cells [13]. This has been shown in a well-character-
ized animal model system of allergic airway inflammation
and airway hyperresponsiveness [11,14,15]. In addition,
airway epiphilium constitutively expresses BDNF but not
NGF, and BDNF production is further enhanced during
inflammatory responses. Further to animal model systems,
enhanced neurotrophin production has also been shown
in patients with several allergic conditions. The initial
report of enhanced NGF production was provided by
Bonini et al, indicating that patients with severe allergic
BA display high serum levels of NGF [16]. Furthermore,
increases in NGF serum levels have been demonstrated in
patients with vernal ceratonconjunctivities and allergic
rhinoconjunctivities [17]. Together with the group of
Virchow  et al, we have more recently shown that neu-
rotrophin production is increased in bronchoalveolar
lavage fluids from patients undergoing segmental allergen
provocation. BDNF and NGF levels were particularly
increased 18 hours after provocation, whereas no
increases were detected 20 min after provocation [18].
These data again indicate local production and release of
neurotrophins on stimulation, and increased levels of neu-
rotrophins are associated with late-phase allergic
responses, but not with the early-phase response.
What are the functional effects of increased neurotrophin
production during the allergic response? Based on the
data provided by other workers and our group, we
propose the concept that neurotrophins play an important
role in the pathophysiology of asthma in several ways
(Fig. 1). The predominant effect on peripheral nerves is
described by the term ‘neuronal plasticity’, which is
defined as qualitative and/or quantitative changes in the
functional activity and capacity of peripheral neurons.
Examples include increased production of neuropeptides
and tachykinins, increased receptor expression, increases
in the number of nerves producing certain neuropeptides
and tachykinins, and lowering of the firing threshold of
nerves. For all these effects, there are ample examples
provided by studies conducted either in animal model
systems or using human cell cultures [19–24]. Initial
studies were carried out by Undem et al, demonstrating
allergen-induced sensory neuroplasticity in guinea pig
airways [25] and NGF-induced phenotypic switch in
airway sensory neurons [26]. One result of these func-
tional alterations is the development of airway hyper-
responsiveness in BA.c
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In parallel, neurotrophins also exhibit profound effects on
immune cells residing in airways and lung tissue. These
effects are described by the term ‘immunological plastic-
ity’. In this regard, neurotrophins act as amplifiers of the
locally occurring immune dysbalance. This effect has so
far exclusively been demonstrated for NGF, but not for
BDNF. NGF augments the production of IL-4 and IL-5 but
not IFN-γ on activation of lymphocytes with allergen. Fur-
thermore, these increases result in enhanced levels of IgE
and IgG1 but not IgG2a antibodies [11].
Conclusion
It is important to note that the effects of neurotrophins are
not immediate, but rather long acting. In this context, we
propose the concept that neurotrophins act as intermedi-
ate or long-acting modulators of neuronal and immune
functions in the pathogenesis of BA. Data on the kinetics
of local neurotrophin production (manuscript in prepara-
tion) support this concept because peak levels of neu-
rotrophin content in bronchoalveolar lavage fluid have
been detected 7–10 days following local allergen chal-
lenges, and these levels return to baseline level no sooner
than 3 weeks after allergen provocation.
Further experiments are certainly required to further evalu-
ate this concept. Treatment modalities particularly need to
be explored, aimed to locally antagonize increased neu-
rotrophin production. Neurotrophins may, however, repre-
sent the ‘common’ trunk of immune and nerve cell
modulators. This may lead to similar clinical signs and
symptoms (e.g. airway hyperresponsiveness and airway
obstruction owing to enhanced airway smooth muscle
contractility, mucus hypersecretion and edema) observed
in asthma patients, regardless of the underlying cause
(e.g. allergen-induced asthma, airway hyperresponsive-
ness in association with viral infections, exercise-induced
asthma, etc.).
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